SXTC

China SXT Pharmaceuticals, Inc. (SXTC) ESG Analysis Analysis (2026)

Invetso Score: 5.2/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 4.8 (Moderate)

Zero reported R&D intensity suggests limited environmental innovation investment versus peers, which can slow adoption of cleaner processes and product redesign.

No disclosed capital allocation to research and development weakens visibility into environmental transition planning, while peers with active programs typically show clearer decarbonization pathways.

Available metrics do not indicate elevated leverage-driven environmental risk, but the absence of explicit emissions, energy, or waste disclosures leaves SXTC less transparent than better-reporting peers.

The current data set provides no evidence of superior environmental controls, so SXTC appears broadly average to slightly below peers on environmental disclosure quality.

Social

Score:

Stock-based compensation at 7.3% of revenue indicates meaningful employee incentive use, which can support retention and alignment, though peers often pair this with broader workforce metrics.

The disclosed metrics do not show labor, safety, or human-capital controversies, but limited social disclosure reduces comparability versus peers with more comprehensive reporting.

No evidence of material social risk is visible in the provided data, yet the lack of diversity, training, and turnover metrics keeps SXTC from ranking above better-disclosed peers.

Overall social positioning appears middling because the company shows some employee-alignment discipline, but peer-relative transparency remains limited across key workforce indicators.

Governance

Score:

Debt-to-equity of 0.04 suggests conservative balance-sheet governance, which lowers creditor pressure and compares favorably with more leveraged peers.

Net debt to EBITDA of 3.23 indicates moderate leverage, so governance quality is not impaired, but peers with stronger capital discipline typically operate at lower leverage.

Stock-based compensation at 7.3% of revenue is manageable, yet without board, audit, or ownership disclosures, governance assessment remains less complete than for peers.

The available metrics imply acceptable capital discipline, but limited disclosure on oversight structures prevents SXTC from demonstrating stronger governance than higher-transparency peers.

Overall Score

Score:

SXTC ranks as a moderate ESG performer versus peers because disclosure is limited and no material ESG advantage is strong enough to offset that gap.

Score Driver: Limited ESG Disclosure Relative To Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on China SXT Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →